Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-Brachyury-TRICOM Vaccine in Advanced Solid Tumors
NCT02179515Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2014
- Primary completion
- Apr 2017
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MVA-BN-Brachyury in solid tumor, sponsored by National Cancer Institute. Primary endpoints: Number of Participants With Serious and Non-serious Adverse Events up to 23 months, Number of Participants With Dose-Limiting Toxicities at 28 days and 2 more. Started Jun 2014; status: completed.
02
Drugs
MVA-BN-Brachyury
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02179515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179515.